FLT3 and acute myeloid leukemia: Allo-HSCT can improve the prognosis of CN-AML patients with DNMT3A mutation but cannot triumph over the adverse prognostic effect of FLT3-ITD, and TP53 mutation is associated with increased relapse-risk after allo-HSCT (38–40).